Russell Investments Group Ltd. Has $4.15 Million Stake in Janux Therapeutics, Inc. $JANX

Key Points

• Russell Investments Group Ltd. significantly increased its stake in Janux Therapeutics by 15,117.4%, acquiring 152,837 additional shares, bringing its total ownership to 153,848 shares valued at approximately $4.15 million.
• Analysts show strong confidence in Janux Therapeutics, with two firms rating the stock as a Strong Buy and an average price target of $86.90, amid expectations that the company will report negative earnings per share this year.
• Janux Therapeutics has a current stock price of $24.30, with a market capitalization of $1.46 billion, experiencing a 1.3% increase in trading on the latest report day.

Russell Investments Group Ltd. raised its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 15,117.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 153,848 shares of the company's stock after purchasing an additional 152,837 shares during the period. Russell Investments Group Ltd. owned 0.26% of Janux Therapeutics worth $4,154,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC raised its position in shares of Janux Therapeutics by 1,574.0% during the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock worth $45,000 after buying an additional 1,574 shares in the last quarter. US Bancorp DE grew its position in Janux Therapeutics by 2,402.9% during the first quarter. US Bancorp DE now owns 1,727 shares of the company's stock valued at $47,000 after purchasing an additional 1,658 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Janux Therapeutics during the fourth quarter valued at approximately $59,000. FNY Investment Advisers LLC grew its position in Janux Therapeutics by 6,928.6% during the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock valued at $66,000 after purchasing an additional 2,425 shares in the last quarter. Finally, KBC Group NV bought a new stake in Janux Therapeutics in the first quarter worth approximately $66,000. 75.39% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on JANX shares. Raymond James Financial initiated coverage on shares of Janux Therapeutics in a report on Friday, July 11th. They set an "outperform" rating and a $65.00 price objective for the company. Piper Sandler assumed coverage on shares of Janux Therapeutics in a research report on Monday, August 18th. They set an "overweight" rating and a $42.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $86.90.

Janux Therapeutics Trading Up 2.7%

Shares of NASDAQ:JANX traded up $0.63 on Tuesday, hitting $23.64. The company had a trading volume of 459,018 shares, compared to its average volume of 936,698. The stock has a 50 day moving average price of $24.50 and a 200 day moving average price of $27.47. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of -13.13 and a beta of 2.86. Janux Therapeutics, Inc. has a 1-year low of $21.97 and a 1-year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.07). Sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.